Glenmark Pharma’s $613 million (over Rs 2,745 crore) out licensing deal with Sanofi has been approved by the US authorities and has also received an upfront payment of $25 million (over Rs 110 crore) from the French drug-maker. Glenmark Pharmaceuticals SA, a wholly-owned subsidiary of Glenmark Pharmaceuticals, had out licensed its novel monoclonal antibody ‘GBR 500’ aimed at treating digestive system disorders, to French drug-maker Sanofi for as much as $613 million.
As per the deal, the Mumbai-based firm would receive an upfront payment of $50 million from Sanofi. In addition, Glenmark could receive potential success- based development, regulatory and commercial payments at different intervals.
GBR 500 is currently undergoing early-stage human trials as a treatment for Crohn’s disease (a form of inflammatory bowel disease), but is considered to have potential for treatment of other inflammatory conditions, such as multiple sclerosis and ulcerative colitis.
As per the deal, Sanofi will have exclusive marketing rights for products developed using GBR 500 in North America, Europe, Japan, Argentina, Chile and Uruguay, while it will co-market the products with Glenmark in Russia, Brazil, Australia and New Zealand. Glenmark will retain exclusive marketing rights in India and other countries in the rest of the world. The company has six different molecules under different stages of development, including GBR 401, GBR 600, GBR 900. Glenmark had acquired GBR 500 and GBR 600 from a Canadian pharmaceutical company at the early stages of its development.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: